STOCK TITAN

Achieve Life Sciences Inc. - ACHV STOCK NEWS

Welcome to our dedicated news page for Achieve Life Sciences (Ticker: ACHV), a resource for investors and traders seeking the latest updates and insights on Achieve Life Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Achieve Life Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Achieve Life Sciences's position in the market.

Rhea-AI Summary
Achieve Life Sciences, Inc. (ACHV) will announce its first quarter 2024 financial results and provide an update on the cytisinicline development program on May 9, 2024. The company is focused on global development and commercialization of cytisinicline for smoking cessation and nicotine dependence. Investors can access the webcast or conference call for more information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Achieve Life Sciences, Inc. (ACHV) announces CEO John Bencich will present at the Life Science Innovation Northwest 2024 Conference to discuss cytisinicline for smoking cessation. The presentation is scheduled for April 18, 2024, at the Seattle Convention Center.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
conferences
-
Rhea-AI Summary
Achieve Life Sciences, Inc. (ACHV) announces positive financial results for Q4 and year-end 2023, along with significant progress in cytisinicline development program. The company reached an agreement with the FDA on NDA submission requirements, completed an equity financing of up to $124.2 million, and presented positive data from Phase 3 and Phase 2 trials. Achieve plans to initiate an open-label exposure trial in Q2 2024, with the expectation of NDA submission in H1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
Rhea-AI Summary
Achieve Life Sciences (ACHV) announces presentations at SRNT Annual Meeting showcasing positive results from Phase 3 trials of cytisinicline for smoking and vaping cessation. Data indicates increased abstinence rates and minimal adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
none
-
Rhea-AI Summary
Achieve Life Sciences, Inc. (ACHV) to report Q4 and year-end 2023 financial results and provide updates on cytisinicline development program. Webcast and conference call details announced.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
-
Rhea-AI Summary
Achieve Life Sciences, Inc. (ACHV) will participate in investor conferences to discuss cytisinicline for smoking cessation. CEO John Bencich will present at the Life Sciences Investor Forum on March 7, 2024. The company aims for global development and commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
conferences
Rhea-AI Summary
Achieve Life Sciences, Inc. announces FDA agreement on long-term safety data requirements for cytisinicline NDA submission, plans to initiate open-label exposure trial in Q2’24. Achieve also secures $124.2 million financing, including milestone-driven warrants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.19%
Tags
none
-
Rhea-AI Summary
Achieve Life Sciences, Inc. secures $60 million upfront financing with potential for an additional $64.2 million tied to milestone-driven warrants. The funding will support the clinical development of cytisinicline for smoking cessation, aiming for FDA approval by 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.19%
Tags
-
Rhea-AI Summary
Achieve Life Sciences, Inc. (Nasdaq: ACHV) announced participation in upcoming investor conferences. CEO John Bencich will present at the Life Sciences Investor Forum on December 14, 2023, at 10:30 AM ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-42.2%
Tags
conferences
Rhea-AI Summary
ACHV: Achieve Life Sciences Announces Positive Third Quarter 2023 Financial Results and Cytisinicline Development Program Update, Including ORCA-2 JAMA Publication, ORCA-V1 SRNT-E Presentation, ASP Panel Presentation, and Completion of NDA-Supportive Clinical Studies
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags
Achieve Life Sciences Inc.

Nasdaq:ACHV

ACHV Rankings

ACHV Stock Data

150.02M
32.49M
9.28%
26.48%
2.09%
In-Vitro Diagnostic Substance Manufacturing
Manufacturing
Link
US
Seattle

About ACHV

achieve life sciences is a specialty pharmaceutical company committed to advancing cytisine as a smoking cessation aid to overcome the global nicotine addiction epidemic.